AZNCF News and Press, AstraZeneca Plc From 04/16/24

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...

2024-04-10 12:50:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...

2024-04-06 06:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The market’s ri...

2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...

2024-03-11 08:22:37 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-03-08 17:15:31 ET Summary AstraZeneca PLC has seen a modest 3% price rise in the past year, but there are positive factors that could drive price upside in 2024. The company has improved revenue guidance for 2024, after guidance beating 2023 numbers. It also sustains a health...

2024-02-24 20:53:46 ET Summary Topline 36-week data from the phase 2 ALPACAR-360 study using its drug zerlasiran for patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease, expected in Q1 2024. There are four other data readouts/presentations expected ...

2024-02-23 17:58:23 ET Summary Ionis Pharmaceuticals, Inc. reported Q4 2023 earnings this week - revenues increased 34% year-on-year to $788m, comfortably outperforming management's guidance. The stock price of Ionis has dipped in 2024 after a lengthy bull run - current market cap...

2024-02-22 21:01:24 ET Summary Novo Nordisk had a near perfect FY23. Fundamentally, FY24 should look quite similar. In reviewing FY23 results and commentary, we discuss key points like SELECT outcomes; CagriSema progress; and expansion into cardiovascular disease. Though expen...

2024-02-21 11:51:31 ET Summary AstraZeneca PLC has announced a deal to acquire Gracell Biotechnologies Inc., a Chinese company focused on developing cell therapies for cancer and autoimmune diseases. The terms of the acquisition include a cash payment of $10 per Gracell ADR and a ...